Basic Information
| LncRNA/CircRNA Name | LINC00511 |
| Synonyms | NA |
| Region | GRCh38_17:72323123-72640472 |
| Ensemble | ENSG00000227036 |
| Refseq | NR_033876 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR, Western blot, in vitro knockdown, RIP |
| Sample | MCF7, UACC-812, MDA-MB231, breast cancer tissues, adjacent normal tissues, breast cancer tissues, adjacent normal tissues |
| Expression Pattern | up-regulated |
| Function Description | We determined that high LINC00511 expression was an unfavourable prognostic factor for patients with breast cancer. Furthermore, LINC00511 promoted tumour growth by accelerating the G1/S transition and inhibiting apoptosis. At the transcriptional level, ER deficiency directly affected the expression of LINC00511 activated by transcription factor AP-2 (TFAP-2) in breast cancer cells. Moreover, mechanistic investigations demonstrated that ERnegative-associated LINC00511 interacted with enhancer of zeste homologue 2 (EZH2, the catalytic subunit of polycomb repressive complex 2, PRC2) and recruited PRC2 to mediate histone methylation, contributing to the repression of CDKN1B in the nucleus. |
| Pubmed ID | 31395854 |
| Year | 2019 |
| Title | The transcriptional landscape of lncRNAs reveals the oncogenic function of LINC00511 in ER-negative breast cancer |
External Links
| Links for LINC00511 | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |